The immunohistochemical characteristics of breast cancers, such as estrogen receptor (ER), progesterone receptor (PR), HER2 receptor expression, and Ki67, play a crucial role in determining therapeutic options and are also correlated with tumor aggressiveness. This evidence concerns the gene PGR and breast cancer.